Company overview
Quanta Therapeutics develops oral, allosteric small molecule inhibitors targeting undruggable RAS mutations like KRAS G12D and G12V for RAS-driven cancers, including pancreatic, colorectal, lung, and endometrial types. Their Phase 1 pipeline includes QTX3034 (G12D-preferring multi-KRAS), QTX3046 (G12D-selective), and QTX3544 (G12V-preferring multi-KRAS), with CNS-penetrant properties and preclinical proof-of-concept. The company leverages Second Harmonic Generation (SHG) technology for protein conformation detection and has sites in South San Francisco, CA, and Radnor, PA.
https://www.quantatherapeutics.com/ is listed in the NovaPharmaNews Supplier Hub as a CDMO & Manufacturing partner serving United States & Americas. Core focus areas include quanta therapeutics, kras inhibitors, ras cancer therapies, g12d g12v drugs, oncology biopharma.
Industry categories: CDMO & Manufacturing. These tags help R&D, manufacturing, and procurement teams discover vendors aligned with their pipeline stage and compliance requirements.
Structured facts
- Website
- https://www.quantatherapeutics.com/
- Categories
- CDMO & Manufacturing
- Markets served
- United States & Americas
- Keywords
- quanta therapeutics, kras inhibitors, ras cancer therapies, g12d g12v drugs, oncology biopharma
Products & technologies
Therapeutic areas
Markets served
Industry categories
Company timeline
- — Profile published on NovaPharmaNews
- — Profile last updated
Related suppliers in category
Frequently asked questions
- What are Quanta Therapeutics' key capabilities in RAS-targeted therapies?
- Quanta develops allosteric small molecules using SHG technology to modulate RAS signaling complexes, targeting KRAS G12D and G12V mutations with oral, CNS-penetrant inhibitors in Phase 1 trials.
- What is the regulatory status of Quanta's pipeline programs?
- QTX3034, QTX3046, and QTX3544 are in Phase 1 clinical trials for KRAS-mutant solid tumors, with QTX3034 advancing to dose expansion cohorts.
- Where are Quanta Therapeutics' operations located?
- Headquartered in South San Francisco, CA, with an additional site in Radnor, PA.
Related editorial coverage
- AACR 2026: Myocarditis Risk, KRAS Inhibitors, mRNA Advances
- KRAS Inhibitors for NSCLC: Complete Guide to Latest FDA Approvals 2024
- $2M Gene Therapy Cures Need a Financing Model
- A Secure And Intelligent Drug Delivery Model Integrating Neural Networks With Blockchain
- AACR 2024: Daily Oncology Research Roundup
- AACR 2024: Oncology News & Key Takeaways - Day 1
Explore lab tools and QA/QC resources for R&D teams.
